Investment
Features
FeesSafety
Academy
More
Pluang+

IRS scrutiny puts Alpha Architect 1-3 Month Box ETF's tax strategy at risk, prompting a hold rating.

Market News
07 Oct 2026
Seeking Alpha
View Source
Bearish
IRS scrutiny puts Alpha Architect 1-3 Month Box ETF's tax strategy at risk, prompting a hold rating.

The Alpha Architect 1-3 Month Box ETF (BOXX) faces new regulatory risk as the IRS's Notice 2026-62 targets its tax-deferral strategy, potentially affecting returns retroactively. BOXX offers T-bill-like returns with significant tax advantages for investors holding over a year, backed by $14.6 billion in assets and strong liquidity. However, the IRS scrutiny introduces uncertainty that outweighs its structural strengths, leading to a hold rating. Investors should watch for further regulatory developments that could impact BOXX's tax benefits.

The Alpha Architect 1-3 Month Box ETF (BOXX) manages $14.6 billion in assets, offering T-bill-like returns with tax advantages but now faces IRS regulatory risk. For readers following US stocks on Pluang, here is the market snapshot as of Oct 07, 2026 20:31 WIB: breadth was 41 gainers and 107 losers out of 150 stocks. Notable movers included HOOD at USD 108.65 with a 2.99% decline, MU at USD 1,014.37 down 2.98%, and B at USD 39.53 falling 2.92%.

More News

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...

Analyst Insights
Neutral
56 minutes ago
Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...

Market News
Bearish
1 hour ago
Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...

Analyst Insights
Bullish
1 hour ago
Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...

Analyst Insights
Bullish
2 hours ago
Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App